Lexicon Pharmaceuticals (LXRX) Receives a Hold from Needham
TipRanks (Fri, 22-Nov 12:45 PM ET)
Lexicon falls on restructuring program
Seeking Alpha News (Fri, 22-Nov 8:02 AM ET)
Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Globe Newswire (Fri, 22-Nov 7:32 AM ET)
Lexicon Pharmaceuticals Appoints Ivan Cheung to Board
TipRanks (Wed, 20-Nov 4:33 PM ET)
Lexicon Appoints Ivan H. Cheung to Board of Directors
Globe Newswire (Wed, 20-Nov 4:10 PM ET)
Globe Newswire (Thu, 14-Nov 8:00 AM ET)
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
Globe Newswire (Tue, 12-Nov 4:05 PM ET)
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference
Globe Newswire (Wed, 6-Nov 8:00 AM ET)
Globe Newswire (Tue, 5-Nov 4:05 PM ET)
Globe Newswire (Tue, 5-Nov 8:00 AM ET)
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.
As of November 22, 2024, LXRX stock price climbed to $0.86 with 9,075,904 million shares trading.
LXRX has a beta of 2.83, meaning it tends to be more sensitive to market movements. LXRX has a correlation of 0.12 to the broad based SPY ETF.
LXRX has a market cap of $312.11 million. This is considered a Small Cap stock.
Last quarter Lexicon Pharmaceuticals reported $2 million in Revenue and -$.18 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.02.
In the last 3 years, LXRX traded as high as $5.22 and as low as $.73.
The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, VXF, IWM, VTWO, SCHA.
LXRX has underperformed the market in the last year with a price return of -20.1% while the SPY ETF gained +32.9%. LXRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -54.8% and -33.6%, respectively, while the SPY returned +6.5% and 0.0%, respectively.
LXRX support price is $.72 and resistance is $.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX shares will trade within this expected range on the day.